Form 4: Sana Biotechnology Director Hans Edgar Bishop Acquires Stock Options

Director Hans Edgar Bishop acquired stock options for 54,278 shares of Sana Biotechnology, Inc. on June 6, 2024.

Summary

• Hans Edgar Bishop, a director of Sana Biotechnology, Inc., acquired stock options for 54,278 shares on June 6, 2024.
• The options have an exercise price of $7.36.
• The options vest on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana Biotechnology through that date.
• The expiration date for the options is June 5, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not inherently convey positive or negative sentiment. It simply reports a transaction.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in biotech companies like Sana Biotechnology.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates